Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
3 Downloads (Pure)


AIM: Patent ductus arteriosus (PDA) is treated with ibuprofen and it is known that the clearance of ibuprofen increases with postnatal age. We aimed to study whether postnatal age-adjusted ibuprofen dosages improve the effectiveness of treatment compared to standard ibuprofen dosages after the first days of life.

METHODS: A historical cohort of 207 preterm neonates treated with standard ibuprofen dosages (Group A; 2011-2015) was compared to a prospective cohort of 66 preterm neonates treated with postnatal age-adjusted ibuprofen dosages (Group B; 2015-2016).

RESULTS: Both groups had comparable background characteristics. Treatment was started after median 6 (25-75th percentile: 4-11) and 5 (25-75th percentile: 4-11) days and effectiveness was 33.2 and 44.7% (p = .17) in groups A and B, respectively. No hemodynamically significant PDA was found in 23/49 (46.9%) of the patients born before 28 weeks after adjusted ibuprofen dosages compared to 48/162 (29.6%) after standard ibuprofen dosages (p = .04). There were significantly more reversible side effects with the postnatal age-adjusted ibuprofen dosages (p = .04).

CONCLUSIONS: There seems to be a trend to higher effectiveness with the adjusted ibuprofen dosages in preterm neonates before 28 weeks, but it is associated with more reversible side effects.

Original languageEnglish
Pages (from-to)2411-2417
Number of pages7
JournalJournal of Maternal-Fetal and Neonatal Medicine
Issue number15
Publication statusPublished - Aug 2021


Dive into the research topics of 'Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus'. Together they form a unique fingerprint.

Cite this